30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Eiger BioPharmaceuticals Inc (EIGR)

Track

Stock chart
Ticker: EIGR Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
KAYNE RICHARD A
1 purchase — total 6,966 USD
Buy 2 Nov 2023
Value US$4,036,520.48 | Price 242.97 | Shares 41,565
Buy 1 Nov 2023
Value US$4,506,006.60 | Price 384.97 | Shares 51,213
Buy 31 Oct 2023
Value US$3,228.22 | Price 0.26 | Shares 12,345
Buy 31 Oct 2023
Value US$3,146.59 | Price 0.26 | Shares 11,987
Buy 31 Oct 2023
Value US$31,504.87 | Price 0.24 | Shares 130,509
Buy 31 Oct 2023
Value US$3,228.22 | Price 0.26 | Shares 12,345
Buy 31 Oct 2023
Value US$3,146.59 | Price 0.26 | Shares 11,987
Sale 17 Mar 2023
Value US$2,007.56 | Price 1.07 | Shares 1,875
Sale 17 Mar 2023
Value US$2,696.40 | Price 1.07 | Shares 2,520
Buy 23 Jan 2023
Value US$71,580.00 | Price 1.43 | Shares 50,000
Sale 29 Dec 2022
Value US$6,104.00 | Price 1.22 | Shares 5,000
Buy 22 Dec 2022
Value US$127,950.00 | Price 1.28 | Shares 100,000
Sale 22 Dec 2022
Value US$26,302.50 | Price 1.17 | Shares 22,500
Planned sale 16 Aug 2022
Value US$49,030.50 | Price 9.81 | Shares 5,000
Sale 14 Mar 2022
Value US$9,274.73 | Price 5.60 | Shares 1,657
Sale 14 Mar 2022
Value US$12,683.48 | Price 5.60 | Shares 2,266
Sale 7 Jan 2022
Value US$7,722.16 | Price 4.95 | Shares 1,560
Sale 15 Mar 2021
Value US$20,280.00 | Price 10.14 | Shares 2,000
Sale 8 Jan 2021
Value US$19,739.20 | Price 11.68 | Shares 1,690
Buy 12 Aug 2020
Value US$51,465.15 | Price 11.44 | Shares 4,500
Buy 12 Aug 2020
Value US$5,637.50 | Price 11.28 | Shares 500
Buy 11 Aug 2020
Value US$57,463.50 | Price 11.49 | Shares 5,000
Buy 16 Mar 2020
Value US$150,813.00 | Price 5.03 | Shares 30,000
Buy 16 Mar 2020
Value US$4,950.00 | Price 4.95 | Shares 1,000
Buy 24 Jan 2020
Value US$67,602.50 | Price 13.52 | Shares 5,000
Buy 10 Jan 2020
Value US$55,760.00 | Price 13.94 | Shares 4,000
Buy 23 Apr 2019
Value US$55,495.00 | Price 11.10 | Shares 5,000
Buy 22 Apr 2019
Value US$11,030.00 | Price 11.03 | Shares 1,000
Buy 22 Apr 2019
Value US$13,852.75 | Price 11.08 | Shares 1,250
Buy 22 Apr 2019
Value US$55,250.00 | Price 11.05 | Shares 5,000
Buy 4 Feb 2019
Value US$3,862.18 | Price 11.26 | Shares 343
Buy 4 Feb 2019
Value US$3,207.51 | Price 14.13 | Shares 227
Buy 20 Dec 2018
Value US$49,900.00 | Price 9.98 | Shares 5,000
Buy 6 Dec 2018
Value US$56,300.00 | Price 11.26 | Shares 5,000
Buy 29 Nov 2018
Value US$40,840.00 | Price 10.21 | Shares 4,000
Buy 27 Nov 2018
Value US$74,407.50 | Price 9.92 | Shares 7,500
Buy 26 Nov 2018
Value US$73,143.00 | Price 9.75 | Shares 7,500
Sale 18 Oct 2018
Value US$317,606.46 | Price 12.00 | Shares 26,465
Sale 18 Oct 2018
Value US$2,544,714.36 | Price 12.07 | Shares 210,800
Sale 2 Apr 2018
Value US$40,000.00 | Price 10.00 | Shares 4,000
Buy 1 Sep 2017
Value US$142,950.00 | Price 9.53 | Shares 15,000
Buy 18 Nov 2016
Value US$5,934.00 | Price 12.90 | Shares 460
Buy 17 Nov 2016
Value US$190,950.00 | Price 12.73 | Shares 15,000
Buy 18 Aug 2016
Value US$21,824.00 | Price 16.00 | Shares 1,364
Buy 18 Aug 2016
Value US$2,978,176.00 | Price 16.00 | Shares 186,136
Buy 18 Aug 2016
Value US$24,523.40 | Price 15.70 | Shares 1,562
Buy 18 Aug 2016
Value US$49,062.50 | Price 15.70 | Shares 3,125
Buy 22 Jun 2016
Value US$9,897.20 | Price 19.79 | Shares 500
Buy 20 Jun 2016
Value US$39,592.40 | Price 19.80 | Shares 2,000
Buy 13 Jun 2016
Value US$9,324.00 | Price 22.20 | Shares 420
Buy 13 Jun 2016
Value US$2,217.00 | Price 22.17 | Shares 100
Buy 13 Jun 2016
Value US$16,176.80 | Price 22.16 | Shares 730
Buy 23 May 2016
Value US$14,892.55 | Price 19.99 | Shares 745
Buy 19 May 2016
Value US$9,760.00 | Price 19.52 | Shares 500
Planned sale 6 Apr 2015
Value US$122,238.76 | Price 18.44 | Shares 6,629
Planned sale 6 Apr 2015
Value US$750,044.32 | Price 18.16 | Shares 41,302
Planned sale 2 Apr 2015
Value US$17,153.40 | Price 16.95 | Shares 1,012
Planned sale 2 Apr 2015
Value US$173,300.00 | Price 17.33 | Shares 10,000
Planned sale 1 Apr 2015
Value US$85,013.72 | Price 19.13 | Shares 4,444
Planned sale 9 Mar 2015
Value US$163,802.59 | Price 24.71 | Shares 6,629
Planned sale 9 Mar 2015
Value US$1,024,702.62 | Price 24.81 | Shares 41,302
Planned sale 6 Mar 2015
Value US$125,000.00 | Price 25.00 | Shares 5,000
Planned sale 6 Mar 2015
Value US$89,920.00 | Price 22.48 | Shares 4,000
Planned sale 6 Mar 2015
Value US$232,900.00 | Price 23.29 | Shares 10,000
Planned sale 5 Mar 2015
Value US$49,038.00 | Price 22.29 | Shares 2,200
Planned sale 5 Mar 2015
Value US$56,250.00 | Price 22.50 | Shares 2,500
Planned sale 2 Mar 2015
Value US$143,718.96 | Price 18.48 | Shares 7,777
Planned sale 9 Feb 2015
Value US$105,666.26 | Price 15.94 | Shares 6,629
Planned sale 9 Feb 2015
Value US$654,636.70 | Price 15.85 | Shares 41,302
Planned sale 6 Feb 2015
Value US$64,320.00 | Price 16.08 | Shares 4,000
Planned sale 6 Feb 2015
Value US$160,800.00 | Price 16.08 | Shares 10,000
Planned sale 2 Feb 2015
Value US$127,153.95 | Price 16.35 | Shares 7,777
Planned sale 9 Jan 2015
Value US$185,100.00 | Price 18.51 | Shares 10,000
Planned sale 7 Jan 2015
Value US$346,000.00 | Price 17.30 | Shares 20,000
Planned sale 6 Jan 2015
Value US$723,198.02 | Price 17.51 | Shares 41,302
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-11-02 2023-11-02 B Purchase
2.2
KAYNE RICHARD A
Large shareholder
41,565 +2.4%
242.97
US$4,036,520 		41,565 +2.4% 242.97 US$4,036,520
2023-11-02 2023-11-01 B Purchase
2.2
KAYNE RICHARD A
Large shareholder
51,213 +13.0%
384.97
US$4,506,007 		51,213 +13.0% 384.97 US$4,506,007
2023-11-02 2023-10-31 B Purchase
1.5
KAWAS LEEN
Large shareholder
57,459 +17.0%
74.72
US$2,917,720 		57,459 +17.0% 74.72 US$2,917,720
2023-11-02 2023-10-31 B Purchase
1.5
KAWAS LEEN
Large shareholder
11,987 +0.3%
0.26
US$3,147 		11,987 +0.3% 0.26 US$3,147
2023-11-02 2023-10-31 B Purchase
2.2
KAYNE RICHARD A
Large shareholder
130,509 +2.5%
0.24
US$31,505 		130,509 +2.5% 0.24 US$31,505
2023-11-02 2023-10-31 B Purchase
2.2
KAYNE RICHARD A
Large shareholder
12,345 +0.2%
0.26
US$3,228 		12,345 +0.2% 0.26 US$3,228
2023-11-02 2023-10-31 B Purchase
2.2
KAYNE RICHARD A
Large shareholder
11,987 +0.2%
0.26
US$3,147 		11,987 +0.2% 0.26 US$3,147
2023-03-21 2023-03-17 S Sale
0.7
Mayer Eldon C. III

Ex VP & Chief Commerc. Officer

Officer
1,875 -3.2%
1.07
US$2,008 		1,875 -3.2% 1.07 US$2,008
2023-03-21 2023-03-17 S Sale
0.7
Mayer Eldon C. III

Ex VP & Chief Commerc. Officer

Officer
2,520 -4.2%
1.07
US$2,696 		2,520 -4.2% 1.07 US$2,696
2023-01-25 2023-01-23 B Purchase
1.7
Dietz Thomas John
Non-Executive Director
50,000 +inf%
1.43
US$71,580 		50,000 +inf% 1.43 US$71,580
2023-01-03 2022-12-29 S Sale
2.2
Murray Christine
Non-Executive Director
5,000 -31.2%
1.22
US$6,104 		5,000 -31.2% 1.22 US$6,104
2022-12-27 2022-12-22 B Purchase
3.4
Glenn Jeffrey S
Non-Executive Director
100,000 +121.4%
1.28
US$127,950 		100,000 +121.4% 1.28 US$127,950
2022-12-27 2022-12-22 S Sale
1.7
Dietz Thomas John
Non-Executive Director
22,500 -51.7%
1.17
US$26,302 		22,500 -51.7% 1.17 US$26,302
2022-08-18 2022-08-16 PlS Planned sale
Apelian David
Non-Executive Director
5,000 -31.2%
9.81
US$49,030 		5,000 -31.2% 9.81 US$49,030
2022-03-14 2022-03-14 S Sale
0.7
Mayer Eldon C. III

Ex VP & Chief Commerc. Officer

Officer
1,657 -2.7%
5.60
US$9,275 		1,657 -2.7% 5.60 US$9,275
2022-03-14 2022-03-14 S Sale
2.7
Ryali Sriram

Chief Financial Officer

Officer
2,266 -5.2%
5.60
US$12,683 		2,266 -5.2% 5.60 US$12,683
2022-01-11 2022-01-07 S Sale
0.7
Mayer Eldon C. III

Ex VP & Chief Commerc. Officer

Officer
1,560 -3.3%
4.95
US$7,722 		1,560 -3.3% 4.95 US$7,722
2021-03-15 2021-03-15 S Sale
2.8
Loh Evan
Non-Executive Director
2,000 -20.0%
10.14
US$20,280 		2,000 -20.0% 10.14 US$20,280
2021-01-11 2021-01-08 S Sale
0.7
Mayer Eldon C. III

Ex VP & Chief Commerc. Officer

Officer
1,690 -4.5%
11.68
US$19,739 		1,690 -4.5% 11.68 US$19,739
2020-08-12 2020-08-12 B Purchase
3.4
Glenn Jeffrey S
Non-Executive Director
4,500 +900.0%
11.44
US$51,465 		4,500 +900.0% 11.44 US$51,465
2020-08-12 2020-08-12 B Purchase
3.4
Glenn Jeffrey S
Non-Executive Director
500 +inf%
11.28
US$5,638 		500 +inf% 11.28 US$5,638
2020-08-12 2020-08-11 B Purchase
3.4
Glenn Jeffrey S
Non-Executive Director
5,000 +7.5%
11.49
US$57,464 		5,000 +7.5% 11.49 US$57,464
2020-03-17 2020-03-16 B Purchase
3.4
Glenn Jeffrey S
Non-Executive Director
30,000 +82.5%
5.03
US$150,813 		30,000 +82.5% 5.03 US$150,813
2020-03-17 2020-03-16 B Purchase
1.7
Dietz Thomas John
Non-Executive Director
1,000 +3.4%
4.95
US$4,950 		1,000 +3.4% 4.95 US$4,950
2020-01-30 2020-01-24 B Purchase
0.7
Mayer Eldon C. III

Ex VP & Chief Commerc. Officer
5,000 +20.0%
13.52
US$67,602 		5,000 +20.0% 13.52 US$67,602
2020-01-13 2020-01-10 B Purchase
1.7
Dietz Thomas John
4,000 +20.0%
13.94
US$55,760 		4,000 +20.0% 13.94 US$55,760
2019-04-23 2019-04-23 B Purchase
1.7
Dietz Thomas John
5,000 +33.3%
11.10
US$55,495 		5,000 +33.3% 11.10 US$55,495
2019-04-22 2019-04-22 B Purchase
1.7
Patton Stephana Eilene

See Remarks
1,000 +33.3%
11.03
US$11,030 		1,000 +33.3% 11.03 US$11,030
2019-04-22 2019-04-22 B Purchase
2.7
Ryali Sriram

Chief Financial Officer
1,250 +inf%
11.08
US$13,853 		1,250 +inf% 11.08 US$13,853
2019-04-22 2019-04-22 B Purchase
1.7
Dietz Thomas John
5,000 +50.0%
11.05
US$55,250 		5,000 +50.0% 11.05 US$55,250
2019-04-26 2019-02-04 B Purchase
0.7
Cory David A

President and CEO

Executive Director
343 +0.5%
11.26
US$3,862 		343 +0.5% 11.26 US$3,862
2019-02-06 2019-02-04 B Purchase
0.7
Cory David A

President and CEO

Executive Director
227 +0.4%
14.13
US$3,208 		227 +0.4% 14.13 US$3,208
2018-12-20 2018-12-20 B Purchase Dietz Thomas John Non-Executive Director
5,000 +100.0%
9.98
US$49,900 		5,000 +100.0% 9.98 US$49,900
2018-12-10 2018-12-06 B Purchase Dietz Thomas John Non-Executive Director
5,000 +inf%
11.26
US$56,300 		5,000 +inf% 11.26 US$56,300
2018-11-30 2018-11-29 B Purchase Mayer Eldon C. III Non-Executive Director
4,000 +19.0%
10.21
US$40,840 		4,000 +19.0% 10.21 US$40,840
2018-11-28 2018-11-27 B Purchase Mayer Eldon C. III Non-Executive Director
7,500 +100.0%
9.92
US$74,408 		7,500 +100.0% 9.92 US$74,408
2018-11-28 2018-11-26 B Purchase Mayer Eldon C. III Non-Executive Director
7,500 +inf%
9.75
US$73,143 		7,500 +inf% 9.75 US$73,143
2018-10-22 2018-10-18 S Sale INTERWEST PARTNERS X LP Large shareholder
26,465 -1.9%
12.00
US$317,606 		26,465 -1.9% 12.00 US$317,606
2018-10-22 2018-10-18 S Sale INTERWEST PARTNERS X LP Large shareholder
210,800 -13.2%
12.07
US$2,544,714 		210,800 -13.2% 12.07 US$2,544,714
2018-04-04 2018-04-02 S Sale Quan Joanne

Chief Medical Officer
4,000 -100.0%
10.00
US$40,000 		4,000 -100.0% 10.00 US$40,000
2017-09-05 2017-09-01 B Purchase Glenn Jeffrey S
15,000 +91.7%
9.53
US$142,950 		15,000 +91.7% 9.53 US$142,950
2016-11-21 2016-11-18 B Purchase Glenn Jeffrey S Non-Executive Director
460 +inf%
12.90
US$5,934 		460 +inf% 12.90 US$5,934
2016-11-21 2016-11-17 B Purchase Glenn Jeffrey S Non-Executive Director
15,000 +1107.0%
12.73
US$190,950 		15,000 +1107.0% 12.73 US$190,950
2016-08-22 2016-08-18 B Purchase Vivo Ventures VI, LLC Large shareholder
1,364 +11.7%
16.00
US$21,824 		1,364 +11.7% 16.00 US$21,824
2016-08-22 2016-08-18 B Purchase Vivo Ventures VI, LLC Large shareholder
186,136 +11.7%
16.00
US$2,978,176 		186,136 +11.7% 16.00 US$2,978,176
2016-08-19 2016-08-18 B Purchase Cory David A

President and CEO

Executive Director
1,562 +2.7%
15.70
US$24,523 		1,562 +2.7% 15.70 US$24,523
2016-08-19 2016-08-18 B Purchase Shaffer James P

Chief Business Officer

Officer
3,125 +125.3%
15.70
US$49,062 		3,125 +125.3% 15.70 US$49,062
2016-06-22 2016-06-22 B Purchase WELCH JAMES H

Chief Financial Officer

Officer
500 +25.0%
19.79
US$9,897 		500 +25.0% 19.79 US$9,897
2016-06-22 2016-06-20 B Purchase WELCH JAMES H

Chief Financial Officer

Officer
2,000 +inf%
19.80
US$39,592 		2,000 +inf% 19.80 US$39,592
2016-06-14 2016-06-13 B Purchase Shaffer James P

Chief Business Officer

Officer
420 +20.2%
22.20
US$9,324 		420 +20.2% 22.20 US$9,324
2016-06-14 2016-06-13 B Purchase Shaffer James P

Chief Business Officer

Officer
100 +5.1%
22.17
US$2,217 		100 +5.1% 22.17 US$2,217
2016-06-14 2016-06-13 B Purchase Shaffer James P

Chief Business Officer

Officer
730 +58.6%
22.16
US$16,177 		730 +58.6% 22.16 US$16,177
2016-05-23 2016-05-23 B Purchase Shaffer James P

Chief Business Officer

Officer
745 +149.0%
19.99
US$14,893 		745 +149.0% 19.99 US$14,893
2016-05-23 2016-05-19 B Purchase Shaffer James P

Chief Business Officer

Officer
500 +inf%
19.52
US$9,760 		500 +inf% 19.52 US$9,760
2015-04-07 2015-04-06 PlS Planned sale ZSEBO KRISZTINA M

Chief Executive Officer

Executive Director
6,629 -68.0%
18.44
US$122,239 		6,629 -68.0% 18.44 US$122,239
2015-04-07 2015-04-06 PlS Planned sale ZSEBO KRISZTINA M

Chief Executive Officer

Executive Director
41,302 -80.9%
18.16
US$750,044 		41,302 -80.9% 18.16 US$750,044
2015-04-03 2015-04-02 PlS Planned sale LABA REBECQUE J

VP, Corporate Operations

Officer
1,012 -25.9%
16.95
US$17,153 		1,012 -25.9% 16.95 US$17,153
2015-04-03 2015-04-02 PlS Planned sale LABA REBECQUE J

VP, Corporate Operations

Officer
10,000 -71.9%
17.33
US$173,300 		10,000 -71.9% 17.33 US$173,300
2015-04-03 2015-04-01 PlS Planned sale TAKEYA RYAN K

VP, Manufacturing

Officer
4,444 -75.6%
19.13
US$85,014 		4,444 -75.6% 19.13 US$85,014
2015-03-09 2015-03-09 PlS Planned sale ZSEBO KRISZTINA M

Chief Executive Officer

Executive Director
6,629 -68.0%
24.71
US$163,803 		6,629 -68.0% 24.71 US$163,803
2015-03-09 2015-03-09 PlS Planned sale ZSEBO KRISZTINA M

Chief Executive Officer

Executive Director
41,302 -80.9%
24.81
US$1,024,703 		41,302 -80.9% 24.81 US$1,024,703
2015-03-09 2015-03-06 PlS Planned sale Honig Peter Non-Executive Director
5,000 -100.0%
25.00
US$125,000 		5,000 -100.0% 25.00 US$125,000
2015-03-09 2015-03-06 PlS Planned sale LABA REBECQUE J

VP, Corporate Operations

Officer
4,000 -58.0%
22.48
US$89,920 		4,000 -58.0% 22.48 US$89,920
2015-03-09 2015-03-06 PlS Planned sale LABA REBECQUE J

VP, Corporate Operations

Officer
10,000 -59.2%
23.29
US$232,900 		10,000 -59.2% 23.29 US$232,900
2015-03-09 2015-03-05 PlS Planned sale Honig Peter Non-Executive Director
2,200 -100.0%
22.29
US$49,038 		2,200 -100.0% 22.29 US$49,038
2015-03-09 2015-03-05 PlS Planned sale Honig Peter Non-Executive Director
2,500 -53.2%
22.50
US$56,250 		2,500 -53.2% 22.50 US$56,250
2015-03-03 2015-03-02 PlS Planned sale TAKEYA RYAN K

VP, Manufacturing

Officer
7,777 -84.4%
18.48
US$143,719 		7,777 -84.4% 18.48 US$143,719
2015-02-10 2015-02-09 PlS Planned sale ZSEBO KRISZTINA M

Chief Executive Officer

Executive Director
6,629 -68.0%
15.94
US$105,666 		6,629 -68.0% 15.94 US$105,666
2015-02-10 2015-02-09 PlS Planned sale ZSEBO KRISZTINA M

Chief Executive Officer

Executive Director
41,302 -80.9%
15.85
US$654,637 		41,302 -80.9% 15.85 US$654,637
2015-02-10 2015-02-06 PlS Planned sale LABA REBECQUE J

VP, Corporate Operations

Officer
4,000 -58.0%
16.08
US$64,320 		4,000 -58.0% 16.08 US$64,320
2015-02-10 2015-02-06 PlS Planned sale LABA REBECQUE J

VP, Corporate Operations

Officer
10,000 -59.2%
16.08
US$160,800 		10,000 -59.2% 16.08 US$160,800
2015-02-03 2015-02-02 PlS Planned sale TAKEYA RYAN K

VP, Manufacturing

Officer
7,777 -84.4%
16.35
US$127,154 		7,777 -84.4% 16.35 US$127,154
2015-01-12 2015-01-09 PlS Planned sale RUDY JEFFREY J

VP, Clinical Operations

Officer
10,000 -90.7%
18.51
US$185,100 		10,000 -90.7% 18.51 US$185,100
2015-01-08 2015-01-07 PlS Planned sale LABA REBECQUE J

VP, Corporate Operations

Officer
20,000 -87.4%
17.30
US$346,000 		20,000 -87.4% 17.30 US$346,000
2015-01-08 2015-01-06 PlS Planned sale ZSEBO KRISZTINA M

Chief Executive Officer

Executive Director
41,302 -93.0%
17.51
US$723,198 		41,302 -93.0% 17.51 US$723,198
Explore more

More insider trading research around Eiger BioPharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America